Background: Sacral nerve modulation (SNM) is an established treatment for urinary and fecal incontinence in patients for whom conservative management has failed. Objective: This study assessed the outcome and cost analysis of SNM compared to alternative medical and surgical treatments.
U rinary and fecal incontinence are socially disabling conditions that greatly affect a patient's quality of life (QOL). 1 Urinary incontinence is generally classified as urge incontinence (involuntary urine leakage accompanied or immediately preceded by urgency), stress incontinence (involuntary urine leakage during effort or exertion), or mixed incontinence (both urge and stress incontinence). 1 Fecal incontinence refers to the uncontrolled loss of solid or liquid stools.
The prevalence of urinary incontinence in middle-aged adults is reported to be between 14% and 41%, with urge incontinence accounting for 22% of cases in women and 73% in men. 2, 3 The prevalence of anal incontinence in women with symptoms of urinary incontinence is estimated to be between 20% and 30%. 4, 5 Fecal incontinence affects approximately 8% of the noninstitutionalized adults' population, and the rate increases with age. 6 Approximately 40% of men and women with anal incontinence also have urinary incontinence. 7 Urinary and fecal incontinence place a significant economic burden on both society and health care systems. In the United Kingdom, the estimated total direct cost to the National Health Service of the treatment of urinary and fecal incontinence was more than £500 million in 2001. 8 Many patients with urge urinary or fecal incontinence can be managed by pharmaceutical products such as antimuscarinic therapy for urge urinary incontinence and loperamide or codeine phosphate for fecal incontinence and/or behavioral techniques such as biofeedback training. 9, 10 However, when conservative treatments fail, sacral nerve modulation (SNM) is considered to be a first-line surgical treatment for patients with urge urinary incontinence 11 and for patients with fecal incontinence and intact anal sphincter muscles. 12 The efficacy of SNM in patients with urge urinary and/or fecal incontinence has been reported in numerous studies. 11, 13 However, limited data are available on the economic impact of SNM in patients with urge urinary and/or fecal incontinence. [14] [15] [16] [17] [18] In addition, most reports on SNM involve uncontrolled studies, with a small number of patients from a single center. 14, 15, 17 Furthermore, there are no studies reporting the treatment of double incontinence (urge urinary and fecal incontinence) with SNM.
The aim of the present study was to prospectively assess the clinical outcome and costs associated with SNM in patients with urge urinary, fecal, or double incontinence and compare these results with the costs associated with alternative medical or surgical treatments.
PATIENTS AND METHODS

Patient Demographics
Between February 2003 and February 2006, 372 consecutive patients with urge urinary and/or fecal incontinence were evaluated for SNM at 20 institutions. Demographic data and follow-up were not available for 3 of these patients.
Two hundred seven patients (188 women, 19 men) with a median age of 56 years (range, 21-83) underwent SNM due to severe urge urinary incontinence per International Continence Society standards. 19 All previous attempts with conservative treatments had failed ( Table 1 ). The median preoperative duration of symptoms was 7 years (range, . Exclusion criteria were any organic pathology causing urge urinary incontinence, congenital malformation, anatomical limitations preventing surgical access, previous bladder resection, and pregnancy.
One hundred sixty-two patients (146 women, 16 men) with a median age of 59 years (range, 23-83) underwent SNM for fecal incontinence, after surgical and conservative treatments (medical treatment or biofeedback) had failed ( Table 1) . All had had a minimum of 1 occasion of fecal incontinence (solid and/or liquid stools) per week, for a median of 5 years (range, 0.3-46) before treatment. Exclusion criteria were any organic disease causing fecal incontinence; congenital malformations; anatomic limitations preventing surgical access; previous rectal surgery such as rectopexy; rectal resection, if performed within the previous 24 months; current rectal prolapse; chronic bowel disease (inflammatory bowel disease such as Crohn disease and ulcerative colitis); chronic diarrhea refractory to medical treatment; and pregnancy.
Seventeen (8%) of the patients whose main symptom was urge urinary incontinence also had fecal incontinence. However, 68 (42%) of the patients whose main symptom was fecal incontinence also had urinary incontinence. Three groups of patients were assessed separately:
1. Patients with urge urinary incontinence alone (n = 190; 18 men, median age = 56 years; range, 21-83); 2. Patients with fecal incontinence alone (n = 94; 12 men, median age = 58 years; range, 23-80); 3. Patients with urinary and fecal incontinence (double incontinence) (n = 85; 5 men, median age = 61 years; range, 26-80).
Ethical approval for the collection of data was granted by the National Committee of Computer Science and Freedom (February 6, 2003, Paris, France). Informed consent was obtained from the patients before they were recruited for the study. 
Sacral Nerve Modulation Procedure
The surgical procedure and equipment used for SNM implantation have been described previously. 20 Before permanent implantation, patients underwent a 1-to 3-week period of temporary percutaneous stimulation to assess their probable response to the treatment. They were then selected for permanent implantation on the basis of the degree of improvement in continence during temporary stimulation. A 50% or greater improvement in the total number of episodes of either urge urinary or fecal incontinence was required to proceed with the permanent implantation. Patients who had had a permanent quadripolar lead from the outset underwent simultaneous removal of the percutaneous extensions (Medtronic Interstim model 3095) and the placement of the pulse generator (Medtronic Interstim I model 3023) subfascially in the ipsilateral upper part of the buttocks (stage I procedure). Those who had had temporary test leads placed during the first intervention underwent simultaneous implantation of the quadripolar lead and pulse generator (stage II procedure). The initial stimulation parameters were identical for all patients: 210 μsec pulse width, frequency between 10 and 14 Hz, and amplitude adapted to the patient's perception of muscular contraction of the perineum and anal sphincter.
Comparison With Other Therapeutic Options
In the event the temporary stimulation was unsuccessful, the practitioner was free to choose an alternative treatment by using National Institute of Clinical Excellence clinical guidelines. 21, 22 Patients with urge urinary incontinence could continue conservative Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. treatments or undergo augmentation enterocystoplasty, urinary diversion, or bladder wall injection with botulinum toxin. Patients with fecal incontinence underwent a neosphincter procedure (artificial bowel sphincter or stimulated graciloplasty) and antegrade irrigation when the fecal incontinence was associated with constipation or a stoma. The other option was to return to the conservative management of the incontinence (pads, diapers, antidiarrheal medication or laxatives, and biofeedback). Alternative treatments in nonimplanted patients are described in Figure 1 . Because of the small number of nonimplanted patients in each treatment category, there were no differences in the clinical evaluation and cost analysis of the various treatments, and the group of nonimplanted patients was considered as a whole.
Clinical Evaluation
The specific quality-of-life, 35-item, 7-dimension Measurement of Urinary Handicap (MUH) symptom-scoring questionnaire 23 was used to quantify the effects of SNM and other treatments on urge urinary incontinence by scoring urgency and urge urinary incontinence, daytime and nocturnal urinary frequency, stress urinary incontinence, low stream, and other incontinences. The scores for urgency, urge urinary incontinence, and frequency range from 0 (none) to 4 (worse).
The severity of fecal incontinence was scored by using the Vaizey scoring system. 24 The scores range from 0 (perfect continence) to 24 (total incontinence). We chose this severity score because it takes several dimensions of fecal incontinence into account, including the urgent need to defecate, the type and frequency of leakages, the medications taken for diarrhea and/or constipation, and the use of pads.
We assessed QOL by using 2 disease-specific French-validated scores (the Ditrovie scale and the American Society of Colon and Rectal Surgeons QOL questionnaire) and 1 general health questionnaire [36-Item Short Form Health Survey (SF- 36) ]. The repercussions of urge urinary incontinence on QOL were evaluated by using the Ditrovie scale. This is a French questionnaire consisting of 10 items graded from 1 to 5 (1 being the best QOL and 5, the worst) with 4 measures of activity, 2 of emotional repercussion, 2 of self-image, 1 of sleep, and 1 of well-being. 25 The total score corresponds to the mean for each item and ranges from 1 to 5.
The Fecal Incontinence QOL questionnaire is the Frenchvalidated version of the American Society of Colon and Rectal Surgeons questionnaire used to explore QOL in patients with fecal incontinence. 26, 27 The Fecal Incontinence QOL scale has 29 items that explore different aspects of patient's QOL. The items are grouped into 4 scales, namely lifestyle (10 items), coping/behavior (9 items), embarrassment (3 items), and depression/self-perception (7 items). The first 4 categories are scored from 1 to 4 (1 being the poorest QOL and 4 being the best), whereas the fifth is scored from 1 to 5 (1 being the poorest QOL and 5 being the best). A separate QOL score is calculated for each scale. Because each item is equally weighted, the subscores correspond to the mean for each scale (total divided by number of items).
The SF-36 is a widely used, validated, generic health-related QOL questionnaire with 36 items that make up 2 components (physical and psychological). 28 The physical aspect of health includes physical functioning, role-physical, bodily pain, and vitality whereas the psychological aspect of health includes emotional, social functioning, and mental health. Each question is given a score that is later translated to a scale ranging from 0 to 100, with 0 corresponding to the worst health status and 100 to the best. 
Economic Analysis
Resource Use and Unit Costs
At the initial consultation, physicians retrospectively collected clinical and cost data related to the pretest evaluation. Beginning with the temporary stimulation, all the data on the use of resources were prospectively collected by the physicians during follow-up visits (temporary test, implantation, and first-and second-year visits). Costs were broadly divided into 2 groups:
1. Direct medical costs included costs related to diagnostic procedures, therapeutic interventions, medications, admissions, day care treatments, specialist consultations, and out-of-hospital care (such as general practitioner, pads, urinary catheters, etc) related to urinary and/or fecal incontinence during follow-up. 2. Indirect or nonmedical costs included health-related travel costs.
The number of patients needing individual caretakers or nursing home placements was too small to be considered. The costs of specialist and general practitioner consultations, physical therapy, and nursing care were based on the rates listed in the General Nomenclature of Professional Acts. The costs of additional tests performed in day care settings were based on rates of the Common Classification of Medical Acts. The costs of laboratory tests and interventions were based on the Nomenclature of Medical Biology Acts. The costs of inpatient hospital stays were determined by the French Diagnosis Related Groups and the rates by the National Cost Scale by homogeneous group of patients (national rate 2004/2005). If these data were missing, the costs of hospital stays were estimated by the average rate determined by the homogeneous group of patients with the same main diagnosis. The cost of incontinence materials (eg, pads and catheters) depended on where they were purchased from (pharmacy, grocery store, or group purchase) and were estimated by expert opinion and the prices used by distributors in the Lille region. The cost of transportation to and from a hospital was reimbursed by the National Health Insurance and included all forms of transport (train, bus, subway, light medical transport vehicle, ambulance, taxi, and personal transportation). The reimbursement rates corresponded to the real costs paid by the patients and were based on average rates for the actual distance traveled by the patient to reach the hospital.
The direct medical costs associated with SNM for the treatment of urinary and fecal incontinence are summarized in Table 2 . The prices are based on the rates in effect from 2004 to 2006 and are displayed in euros with a median, mean, and standard deviation.
Health Outcome
The cost-effectiveness analysis was performed by comparing 2 different medical care strategies: SNM (implanted group) versus non-SMN (therapeutic alternatives in the nonimplanted group). All the costs related to SNM, including the SNM evaluation and the temporary test stimulation, even in patients in whom SNM failed, were attributed to the cost of the SNM strategy.
The cost-effectiveness analysis was performed by using the incremental cost-effectiveness ratio (ICER) and quality-adjusted life years (QALYs). The ICER was calculated by using the following equation:
ICER =
Cost of SNM -Cost of non-SNM Efficacy of SNM -Efficacy of non-SNM .
The efficacy of the treatments was defined as a 50% improvement in urge urinary and/or fecal incontinence severity scores (urge urinary incontinence item of MUH, and Vaizey scores). Quality-adjusted life year was derived by the conversion of 11 components of the SF-36 QALY health questionnaire into a preference-based, 6-dimensional health state classification (SF-6D). 29 The value of the health state under SF-6D was then calculated on the basis of "Model 10" developed by Brazier et al 30 and used as an estimation of QALY for the cost-effectiveness analysis. The present study was funded by the French Ministry of Health. Its main aim was to provide information for making decisions regarding services provided by the state. In this respect, the perspective for the economic evaluation was that of the French National Health Service.
Follow-up Appointments
As recommended by the position statement, 12 patients eligible for chronic stimulation had 6 postoperative follow-up appointments to identify complications and optimize stimulation settings (1, 3, 6, 12, 18, and 24 months). Thereafter, the patients were followed up annually. Severity scores were determined at 6, 12, 18, and 24 months of follow-up, and QOL and cost questionnaires were completed at 6, 12, 24 months of follow-up. When the patients were not implanted, they were interviewed either during a follow-up visit or by telephone 6, 12, and 24 months after the temporary stimulation.
Statistics
Data are presented as medians, ranges, or means with standard deviations. Statistical analyses for severity scores, QOL, and cost data were performed nonparametrically by using the Wilcoxon matchedpaired signed rank test to compare preoperative and postoperative values. Comparisons of data between implanted and nonimplanted groups were performed by using the Mann-Whitney U test. Because differences between implanted and nonimplanted patients could bias patient outcomes and the costs of the different therapies, the cost analyses were adjusted for baseline differences by using a linear regression to adjust the estimates for relevant covariates (sex, age, and severity and duration of incontinence).
The decision to fund a service is partly based on whether the treatment is cost-effective. However, there are uncertainties associated with expected costs and effectiveness. We explored these uncertainties by using cost-effectiveness planes and acceptability curves. 31 We calculated 95% confidence intervals (CIs) for differential costs and effectiveness by using nonparametric bootstrap estimates (percentile method). One thousand simulations were performed. The results of these simulations are presented by using cost-effectiveness planes. The technique was operationalized in 4 steps: (1) random sampling with the replacement of Nc patients in the reference strategy (Nc: sample size of the reference strategy) and the calculation of average cost and average efficiency of this sample; (2) random sampling with the replacement of Nt patients in the neuromodulation strategy (Nt: sample size of the neuromodulation strategy) and the calculation of average cost and average efficiency of this sample; (3) calculation of the difference of the ICER between the 2 bootstrapped samples; and (4) repetition of the operation 1000 times to obtain an estimation of the distribution of the ICER in the cost-effectiveness plane. 32 A P < 0.05 was considered statistically significant. The analyses were performed by using StatView (SAS Institute, Berkeley, CA).
RESULTS
On the basis of temporary test stimulations in 369 patients, a permanent neurostimulation device was implanted in 248 (67.2%) patients. In 123 (49.6%) of the patients, urge urinary incontinence was the indication; in 60 (24.2%), fecal incontinence; and in 65 (26.2%), double incontinence. In the remaining 121 patients, screening failure (80%) and electrode implantation failure, nonadherence, pain, and infection (20%) prevented permanent implantation.
Two hundred twenty-four of the 248 implanted patients were followed up at 6 months (90.3%), 206 at 12 months (83.1%), 190 at 18 months (76.6%), and 174 at 24 months (70.2%). As expected, the monitoring of nonimplanted patients was more difficult. One hundred three (85.1%) of the 121 nonimplanted patients were followed up at 6 months, 81 (66.9%) at 12 months, 69 (57%) at 18 months, and 62 (51.2%) at 24 months. Details of the follow-ups are given in Figure  1 . In all cases, the alternative treatments were started 6 months after the Temporary Stimulation test.
Resource Use
Temporary Stimulation Test
Two hundred two (56.7%) patients underwent a stage I procedure and 154 (43.3%), a stage II procedure. Whereas only 57 (15.4%) of the temporary SNM were performed under general anesthesia, 337 (91.3%) of the 369 patients stayed for more than 12 hours in hospital. The median hospital stay was 3 days (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . No severe complications were reported during the Temporary Stimulation test. Minor complications (pain, infection, lead displacement, or failure of the external stimulator) occurred in 39 (10.6%) of the 369 patients. In 35 patients (9.5%), the test had to be repeated because of electrode dislocation or loss of effectiveness. The costs for these 35 patients were included in the costs of the temporary stimulation.
Sacral Nerve Modulation
The median hospital stay for the 369 patients who received SNM implants was 4 days (range, 1-16). One hundred forty-four (58.5%) of the 246 implantations were performed under general anesthesia. Immediate complications during implantation of the complete neurostimulation system were rarely observed (5.7%). At the 24month follow-up after implantation, 114 patients (46%) reported device-related adverse events: 52 patients (45.6%) implanted for urge urinary incontinence, 25 (21.9%) for fecal incontinence, and 37 (32.5%) for double incontinence (P = 0.1). Details of complications are given in Table 3 . Overall, 28 (11.3%) of the 248 implanted patients required a second intervention to remove or replace the device. A new device (electrode and/or stimulator) was reimplanted in 3 of them.
Continence Status
Permanent SNM greatly improved the primary outcome measurements in patients with urge urinary and/or fecal incontinence. No significant differences were found in preoperative MUH overactive bladder dimensions between the implanted and nonimplanted groups (Fig. 2) . Postoperative scores for the 4 MUH dimensions of an overactive bladder (urgency, urge urinary incontinence, daytime and nocturnal frequency) decreased significantly in patients implanted for isolated urge urinary (Fig. 2) . However, supplementary oral medication was required by 33 (28%) of these patients due to partial relapse of symptoms. Four (3%) other patients also underwent secondary procedures (botulinum injection or bladder neck suspension) for the same reasons (Fig. 1) . The posttreatment MUH dimensions of overactive bladders of nonimplanted patients also significantly improved compared with the pretreatment dimensions (Fig. 2) . However, the improvement was statistically less significant than for implanted patients (Fig. 2) .
Nonimplanted patients with fecal incontinence had less-severe incontinence than implanted patients according to the baseline score ( Fig. 3) . Severity scores improved significantly in the 60 patients implanted for isolated fecal incontinence from a median of 19 (range, 11-24) before SNM implantation to a median of 12 (range, 0-21), 24 months after implantation (P < 0.001) ( Fig. 3 ). However, other therapies (radiofrequency and colostomy) were provided to 2 patients (3%) because of a relapse of symptoms (<50% improvement from baseline) and patient dissatisfaction (Fig. 1) . No significant improvement was observed in nonimplanted patients after the temporary stimulation (Fig. 3) . The symptom severity score had improved markedly for implanted patients at the 6-month follow-up, but there was no significant difference between implanted and nonimplanted patients thereafter (Fig. 3) . The mean Vaizey score and 2 dimensions of overactive bladder in the MUH (urgency and urge urinary incontinence) decreased significantly in patients with double incontinence after implantation (Figs. 4 and 5). Seven (11%) patients in this group received other treatments for urge urinary incontinence (oral medication for 4 patients and surgery for 3). One patient (2%) with continuing fecal incontinence had an artificial sphincter implanted that was later superseded by a colostomy. Nonimplanted patients with double incontinence showed no significant improvement at 24 months of follow-up ( Figs. 4 and 5) . However, the number of patients was too small to draw any conclusions for this group.
Quality-of-Life Evaluation
The results of the 2 specific QOL questionnaires (Ditrovie and Fecal Incontinence QOL) indicated that SNM had a positive impact independent of the indication for SNM. Implanted patients demonstrated statistically significant improvements compared with nonimplanted patients at 6, 12, and 24 months of follow-up (Tables 4 and 5 ). The effect of stimulation on general health measured by the SF-36 questionnaire was less marked, except for patients implanted for urge urinary incontinence. In this group, there was a significant improvement in all SF-36 domains except for bodily pain and general health ( Table 6 ). 
Total Costs
The median total costs incurred by the treatments are summarized in Table 7 . For nonimplanted patients, the cost of alternative medical and/or surgical treatments was included in the median total costs calculated at each follow-up visit.
The median overall cost per patient in the first 2 years after the SNM treatment was € 16,403 for patients implanted for urge urinary incontinence, € 14,973 for patients implanted for fecal incontinence, and € 14,795 for patients implanted for double incontinence (Table 7) . Devices and hospital stays accounted for 40% and 52% of the total cost, respectively. Because we observed statistically significant differences in the severity of fecal incontinence at baseline ( Fig. 3) , which could have biased patient's outcomes, a cost analysis adjusted for baseline imbalances was performed. The adjusted cost analysis revealed that treating urge urinary incontinence with SNM costed an average of € 8525 more per participant the first 2 years (95% CI, € 6686-€ 10,364) than alternative treatments (P = 0.001). The corresponding value for fecal incontinence was € 6581 (95% CI, € 2077-€ 11,084; P = 0.006) ( Table 8 ).
Cost-effectiveness and Associated Uncertainty
The ICER results and the cost-effectiveness per QALY are given in Table 9 . For fecal incontinence, the cost-effectiveness per QALY was not calculated because implantation was more expensive and less effective in terms of QALY. The number of nonimplanted patients with double incontinence was too small to calculate ICER and cost-effectiveness per QALY.
In the cost-effectiveness plane, bootstrapped incremental costs and utilities were scattered to represent the joint uncertainty distribution. For patients implanted for urge urinary incontinence, the probability that the implantation strategy would be more expensive and more effective was estimated at 0.977 in terms of improving severity and at 0.931 in improving QALY, whereas the probability that it would be more expensive and less effective (ie, dominated) was 0.023 and 0.069, respectively. The 95% CI of the cost-effectiveness ratio was equal to 43,585 to 286,554 if the effectiveness unit was a 50% improvement in the severity score and 153,652 to 555,632 if the effectiveness unit was QALY (Fig. 6) .
For patients implanted for fecal incontinence, the probability that the strategy would be more expensive and more effective in improving the severity of incontinence was 0.762, whereas the probability that it would be more expensive and less effective was 0.238. The CI of the cost-effectiveness ratio could not be estimated (the most expensive and most effective probability was less than 0.950). If the effectiveness unit was QALY, the probability that the strategy would be more expensive and more effective was 0.400, whereas the probability that it would be more expensive and less effective was 0.600 ( Fig. 6 ).
DISCUSSION
Cost-effectiveness of the Treatment
Our prospective multicenter cohort study confirmed that, compared to alternative treatments, SNM improves urinary and/or fecal incontinence and QOL. The median cost of SNM for urge urinary incontinence was €16,403 per patient for the first 2 years. Using a more than 50% improvement in urge urinary continence as the effectiveness unit, ICER was estimated at €94,204 per patient at the 24-month follow-up. In addition, SNM had an ICER of €110,741 per QALY gained. However, despite its costs, SNM was not dominated because it was significantly more effective than alternative treatments. The costs incurred to treat urinary urge incontinence by SNM have been previously investigated in a partial analysis performed in parallel P< 0.01 P = 0.01 P = 0.05 to a retrospective study with 55 patients implanted for urge urinary incontinence. 17 The conclusion of this study was that voiding-related health care costs (ie, office visits, diagnostic and therapeutic procedures, and medication usage) were significantly reduced after SNM. 17 However, limitations associated with the design of this clinical study (ie, lack of a control group and not all costs being taken into account) make it difficult to draw any firm conclusions concerning the cost-effectiveness of SNM as a treatment for urge urinary incontinence. Our results showed that a considerable proportion of the costs attributed to SNM is related to the costs of the devices and hospital stays. These were not included in the previous study. More recently, Siddiqui et al 18 compared the cost-effectiveness of SNM versus botulinum toxin A for the treatment of urge urinary incontinence. a previous study. 33 Our cost-effectiveness analysis confirmed that, compared with alternative treatments, SNM provides marked health benefits for patients with fecal incontinence, as measured by the severity score, but at a higher cost. Twenty-four months after implantation, the ICER rate for improved continence was estimated at €185,160 per patient. In terms of costs per QALY, SNM was equally less effective and was more expensive than alternative treatments. According to Dudding et al, 15 the ICER rate per patient-year of improved continence is £1543 and the ICER per QALY gained is £25,070. However, in this study, an underestimation of the cost of SNM and an overestimation of its efficacy cannot be excluded. The data in this study were not collected prospectively for an economic evaluation. Costs were based on assumptions that could have biased the calculations. Also, the costs of conservative treatments were based on baseline prestimulation data that were considered to be equivalent to the continued use of conservative treatments. Preimplantation costs may have been higher because of more medical examinations and visits for the implantation. In addition, the authors considered that conservative treatments were ineffective. For double incontinence, the median total costs of SNM for the first 2 years of follow-up were similar to those of isolated urge urinary or fecal incontinence (€14,795). Moreover, SNM was signifi-cantly more effective than associated alternative treatments for mixed incontinence. These results suggested that SNM is cost-effective for double incontinence. Unfortunately, the number of nonimplanted patients followed up in this group was too small to estimate the costeffectiveness of SNM for this indication.
To our knowledge, this is the first prospective cohort study to assess the economy and cost-effectiveness of SNM in treating urge urinary and fecal incontinence, with a medium term follow-up period of 24 months. However, there were shortfalls associated with our study that needed to be taken into account. First, it was not a randomized trial. The attrition rate for follow-ups was significant, especially in the nonimplanted group (47.1%). This prevented us from forming homogeneous groups of patients receiving alternative treatments to SNM and making further comparisons with implanted patients. This also meant that the SNM cost-effectiveness values for implanted patients might not be completely accurate. The SF-36 QOL questionnaire is a general health questionnaire. It is not a specific questionnaire for detecting conditions such as urinary or fecal incontinence. 26, 34 Consequently, a slight improvement in SF-36 scores after implantation was not surprising and resulted in a higher cost per QALY gained in implanted patients. Inaccuracies may also have occurred in the measurement of symptom improvement. We chose severity scores that were the easiest to use, especially for telephone interviews. However, this scoring system may not be sensitive enough to detect a 50% improvement in symptoms. 35 Lastly, the cost analysis was based on a 2-year period, and incontinence is a chronic life-long disease. These first 2 years were probably the most expensive, if we consider the total life expectancy of the stimulator (on average, around 7 years). Conversely, we did not take into account the costs induced by the replacement of the stimulator after several years of use.
Use of Strategies
For a greater than 50% improvement in severity scores, ICER was calculated at €94,204 for urge urinary incontinence and €185,160 for fecal incontinence at the 2-year follow-up. These ratios are above the generally accepted ranges for cost-effective therapies. 36, 37 FIGURE 6. Incremental cost-effectiveness acceptability plane of SNM for patients with isolated urge urinary and fecal incontinence. The cost-effectiveness plane consists of 4 quadrants. A dot to the right of the y axis means that SNM yields a better outcome in terms of severity score improvement and quality adjusted life year than conservative treatments. A dot above the x axis means that the costs of SNM are higher than conservative treatments. (A) Patients with isolated urge urinary incontinence. (B) Patients with isolated fecal incontinence.
However, the decision to pay such costs should be based both on the cost-effectiveness and comparisons made with available alternative treatment options. To our knowledge, no randomized trials investigating the effectiveness and costs of alternative treatments have been reported in the literature. For many patients, there are few alternatives, and these patients often do not meet the requirements for these treatments (eg, artificial bowel sphincter), 38 Intravesical botulinum toxin injections seem to be effective and less invasive than SNM in patients with detrusor overactivity. 39 However, the injections need to be repeated regularly, and catheterizations are often required because of induced urinary retention. One study comparing SNM and botulinum toxin concluded that SNM is more cost-effective than botulinum toxin. 18 Unfortunately, our study was not sufficiently powered to compare the cost-effectiveness of these alternatives with SNM.
Our results suggested that, to improve the cost-effectiveness of SNM, the costs must be reduced. This can be achieved by temporary implantations under local anesthetic and in an outpatient's setting, when possible. Complications such as pain are a source of additional costs. Recently, it has been suggested that neuromodulator Interstim II (Medtronic model 3058) implantation is associated with a reduction in pain 15 and may prove to be a cheaper option. In addition, a better selection of patients who may benefit from SNM, thus avoiding the high failure rate of the temporary device and improving the medium-and long-term results of implantation, 40, 41 should also lead to a reduction in the cost of SNM.
CONCLUSIONS
This study showed that, from the French health service perspective, SNM is a cost-effective treatment for urge urinary and fecal incontinence. The costs of this technique are high, but therapeutic alternatives are limited and must be shown to be more cost-effective. However, the present study was carried out in the setting of a specific country. As such, a direct comparison of our results with those of other health care systems might not be possible. On the contrary, the details of this investigation and the sensitivity analyses performed may help others determine whether a study in their specific setting would yield different results.
